# A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

> **NCT00909402** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 39 (actual)

## Conditions studied

- Stomach Neoplasms
- Esophageal Neoplasms

## Interventions

- **DRUG:** BMS-833923
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT00909402
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2013-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909402, "A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00909402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*